Establishing a List of Qualifying Pathogens Under the Food and Drug Administration Safety and Innovation Act

Document Subtype:	Notice of Proposed Rulemaking (NPRM)
Received Date:	June 12 2013, at 12:00 AM Eastern Daylight Time
Start-End Page:	35155 - 35173
Page Count:	19
Comment Start Date:	June 12 2013, at 12:00 AM Eastern Standard Time
Comment Due Date:	August 12 2013, at 11:59 PM Eastern Standard Time

List of References 1 through 157

View Attachment:

Refeence 148 Increase in Pneumococcus Macrolide Resistance United States

View Attachment:

Reference 1 Hospital and Societal Costs of Antimicrobial Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship

View Attachment:

Reference 10 Clinical Outcomes of Health Care Associated Infections and Antimicrobial Resistance in Patients Admitted to European Intensive Care Units: A Cohort Study

View Attachment:

Reference 100 Mechanisms of Antibiotic Resistance in Staphylococcus aureus

View Attachment:

Reference 101 Staphylococcus aureus Resistant to Vancomycin United States 2002

View Attachment:

Reference 102 Clinical Practice Guideline by the Infectious Disease Society of America for the Treatment of Methicillin Resistant Staphylococcus Aureus Infections in Adults and Children

View Attachment:

Reference 103 Resistance of Group B Streptococcus to Selected Antibiotics Including Erythromycin and Clindamycin

View Attachment:

Reference 104 Group B Strep GBS Fast Facts

View Attachment:

Reference 105 Group B Strep Infection in Newborns

View Attachment:

Reference 106 Group B Strep Infection in Adults

View Attachment:

Reference 107 Antibiotic Resistance Patterns in Invasive Group B Streptococcal Isolates

View Attachment:

Reference 108 Mutation in the Group B Streptococcal pbp2x Gene Conferring Decreased Susceptibility to Beta Lactam Antibiotics

View Attachment:

Reference 109 Resistance to Beta Lactam Antibiotics

View Attachment:

Reference 11 Aspergillus Infection in Lung Transplant Patients Incidence and Prognosis

View Attachment:

Reference 110 Genetic Heterogeniety in pbp Genes Among Clinically Isolated Group B Streptococci With Reduced Penicillin Susceptibility

View Attachment:

Reference 111 In Vitro Resistance to Macrolides and Clindamycin by Group B Streptococcus Isolated From Pregnant and Nonpregnant Women

View Attachment:

Reference 112 Infectious Diseases Related to Travel Pneumococcal Disease Streptococcus pneumoniae

View Attachment:

Reference 113 Streptococcus pneumoniae: Does Antimicrobial Resistance Matter

View Attachment:

Reference 114 Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23 Valent Pneumococcal Polysaccharide Vaccine PPSV23

View Attachment:

Reference 115 Disease Listing Streptococcus pneumoniae Disease

View Attachment:

Reference 116 Drug Resistant Streptococcus pneumoniae Rational Antibiotic Choices

View Attachment:

Reference 117 Changing Trends in Antimicrobial Resistance and Serotypes of Streptococcus pneumoniae Isolates in Asian Countries an Asian Network for Surveillance of Resistant Pathogens ANSORP Study

View Attachment:

Reference 118 Antimicrobial Resistance Surveillance in Europe 2009

View Attachment:

Reference 119 The Streptococcus pyogenes Proteome Maps Virulence Factors and Vaccine Candidates

View Attachment:

Reference 12 Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism

View Attachment:

Reference 120 Diagnosis and Management of Adults With Pharyngitis A Cost Effectiveness Analysis

View Attachment:

Reference 121 Group A Streptococcal Pharyngitis and Immune Mediated Complications From Diagnosis to Management

View Attachment:

Reference 122 ABCs Report Group A Streptococcus 2011

View Attachment:

Reference 123 Why Have Group A Streptococci Remained Susceptible to Penicillin Report on a Symposium

View Attachment:

Reference 124 Group A Streptococcus and its Antibiotic Resistance

View Attachment:

Reference 125 Cholera Epidemiology and Risk Factors

View Attachment:

Reference 126 Cholera in the United States 1995 2000: Trends at the End of the Twentieth Century

View Attachment:

Reference 127 Drug Resistance Mechanisms in Vibrio cholerae O1 Outbreak Strain Haiti 2010

View Attachment:

Reference 128 Third Generation Cephalosporin Resistant Vibrio cholerae India

View Attachment:

Reference 129 Toxigenic Vibrio cholerae Serogroup O141 Associated Cholera Like Diarrhea and Bloodstream Infection in the United States

View Attachment:

Reference 13 Azole Antifungal Resistance Today Focus on Aspergillus

View Attachment:

Reference 130 The Current ICE Age Biology and Evolution of SXT Related Integrating Conjugative Elements

View Attachment:

Reference 131 Cholera Treatment

View Attachment:

Reference 132 Antimicrobial Resistant Pathogens Associated With Healthcare Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention 2009 2010

View Attachment:

Reference 133 Pan Resistant Acinetobacter Infection in Neonates in Karachi Pakistan

View Attachment:

Reference 134 National Antimicrobial Resistance Monitoring System Enteric Bacteria: 2010 Human Isolates Final Report

View Attachment:

Reference 135 The Roles of Clostridium difficile and Norovirus Among Gastroenteritis Associated Deaths in the United States 1999 2007

View Attachment:

Reference 136 Making Health Care Safer: Stop Infections from Lethal CRE Germs Now

View Attachment:

Reference 137 Mycobacterium General Characteristics Laboratory Detection and Staining Procedures

View Attachment:

Reference 138 Rifampin Resistant Meningococcal Disease

View Attachment:

Reference 139 Epidemiology of Invasive Meningococcal Disease With Decreased Susceptibility to Penicillin in Ontario Canada 2000 to 2006

View Attachment:

Reference 14 An outbreak of Burkholderia cepacia Bacteremia in Hospitalized Hematology Patients Selectively Affecting Those With Acute Myeloid Leukemia

View Attachment:

Reference 140 Antibiotic Treatment Recommendations for the Use of Antibiotics for the Treatment of Cholera

View Attachment:

Reference 141 Laboratory Based Surveillance of Neisseria meningitides Isolates From Disease Cases in Latin America and Caribbean Countries SIREVA II 2006 2010

View Attachment:

Reference 142 Fluoroquinolone Resistance in Neisseria meningitidis in Spain

View Attachment:

Reference 143 Emergence of Neisseria meningitidis With Decreased Susceptibility to Ciprofloxacin in Argentina

View Attachment:

Reference 144 Mutator Clones of Neisseria meningitidis in Epidemic Serogroup A Disease

View Attachment:

Reference 145 Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus aureus United States 1999 2005

View Attachment:

Reference 146 ABCs Report Methicillin Resistant Staphylococcus aureus 2010

View Attachment:

Reference 147 Emergence of a Multiresistant Serotype 19A Pneumococcal Strain Not Included in the 7 Valent Conjugate Vaccine as an Otopathogen in Children

View Attachment:

Reference 149 Clinical Data in Children With Meningococcal Meningitis in a Spanish Hospital

View Attachment:

Reference 15 Clinical Characteristics and Outcomes of Patients With Burkholderia cepacia Bacteremia in an Intensive Care Unit

View Attachment:

Reference 150 Burkholderia cenocepacia and Burkholderia multivorans Influence on Survival in Cystic Fibrosis

View Attachment:

Reference 151 Overview of Nosocomial Infections Caused by Gram Negative Bacilli

View Attachment:

Reference 152 Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa Our Worst Nightmare

View Attachment:

Reference 153 CDC Grand Rounds The Growing Threat of Multidrug Resistant Gonorrhea

View Attachment:

Reference 154 Antimicrobial Resistance Trends of Shigella Serotypes in New York City 2006 2009

View Attachment:

Reference 155 Antimicrobial Resistance in Nontyphoidal Salmonella

View Attachment:

Reference 156 The Relation Between Farm Specific Factors and Prevalence of Clostridium difficile in Slaughter Pigs

View Attachment:

Reference 157 Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America

View Attachment:

Reference 16 An Episodic Outbreak of Genetically Related Burkholderia cepacia Among Non-Cystic Fibrosis Patients at a University Hospital

View Attachment:

Reference 17 Predictors of Mortality in Adults With Cystic Fibrosis

View Attachment:

Reference 18 Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health

View Attachment:

Reference 19 Antibiotic Resistance in Burkholderia cepacia at Two Regional Centres in Northern Ireland: Is There a Need for Synergy Testing

View Attachment:

Reference 2 The Global Impact of Drug Resistance

View Attachment:

Reference 20 Cystic Fibrosis Foundation Achieving the Mission

View Attachment:

Reference 21 Campylobacter General Information

View Attachment:

Reference 22 Antibiotic Resistance in Campylobacter Emergence Transmission and Persistence

View Attachment:

Reference 23 Antimicrobial Resistance Virulence and Genotypic Profile Comparison of Campylobacter jejuni and Campylobacter coli Isolated from Humans and Retail Meats

View Attachment:

Reference 24 Trends in Antibiotic Sensitivity Pattern and Molecular Detection of tet O Mediated Tetracycline Resistance in Campylobacter jejuni Isolates From Human and Poultry Sources

View Attachment:

Reference 25 Treatment of Invasive Candidiasis in Neutropenic Patients Systematic Review of Randomized Controlled Treatment Trials

View Attachment:

Reference 26 Invasive Candidiasis Statistics

View Attachment:

Reference 27 Risk Factors for Fluconazole Resistant Candidiasis in Human Immunodeficiency Virus Infected Patients

View Attachment:

Reference 28 Epidemiology of Candidaemia and Antifungal Susceptibility Patterns in an Italian Tertiary Care Hospital

View Attachment:

Reference 29 Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients: 2010 Data Report

View Attachment:

Reference 3 Costs of Healthcare and Community Associated Infections With Antimicrobial Resistant Versus Antimicrobial Susceptible Organisms

View Attachment:

Reference 30 Fungal Infections in Solid Organ Transplantation

View Attachment:

Reference 31 Evolution of Anti-Fungal Drug Resistance Mechanisms and Pathogen Fitness

View Attachment:

Reference 32 The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species

View Attachment:

Reference 33 Increase in Candida krusei Infection Among Patients With Bone Marrow Transplantation and Neutropenia Treated Prophylactically With Fluconazole

View Attachment:

Reference 34 ESCMID Guideline for the Diagnosis and Management of Candida Diseases 2012 Adults With Haematological Malignancies and After Haematopoietic Stem Cell Transplantation HCT

View Attachment:

Reference 35 Frequently Asked Questions About Clostridium difficile for Healthcare Providers

View Attachment:

Reference 36 Clostridium difficile Excerpt Guideline for Environmental Infection Control in Health Care Facilities 2003

View Attachment:

Reference 37 Making Healthcare Safer Stopping C difficile Infections

View Attachment:

Reference 38 Clinical Practice Guidelines for Clostridium difficile Infection in Adults 2010 Update by the Society for Healthcare Epidemiology of America SHEA and the Infectious Diseases Society of America IDSA

View Attachment:

Reference 39 Emergence and Global Spread of Epidemic Healthcare-Associated Clostridium difficile

View Attachment:

Reference 4 Principles and Practice of Infectious Diseases. 7th Ed Staphylococcus aureus including Staphylococcal Shock p. 2543 3253

View Attachment:

Reference 40 Carbapenem Resistant Enterobacteriaceae a Review of Treatment and Outcomes

View Attachment:

Reference 41 Preventing Lethal Hospital Outbreaks of Antibiotic Resistant Bacteria

View Attachment:

Reference 42 Foodborne Illness Acquired in the United States Major Pathogens

View Attachment:

Reference 43 Inpatient Care for Septicemia or Sepsis A Challenge for Patients and Hospitals

View Attachment:

Reference 44 Growing Antimicrobial Resistance of Shigella Isolates

View Attachment:

Reference 45 Outbreak of Infections Caused by Shigella sonnei with Reduced Susceptibility to Azithromycin in the United States

View Attachment:

Reference 46 Prevalence and Mechanisms of Cephalosporin Resistance in Enterobacteriaceae in London and South East England

View Attachment:

Reference 47 A Multinational Survey of Risk Factors for Infection with Extended Spectrum beta Lactamase Producing Enterobacteriaceae in Nonhospitalized Patients

View Attachment:

Reference 48 Carbapenem Resistant Enterobacteriaceae

View Attachment:

Reference 49 Klebsiella pneumoniae in Healthcare Settings

View Attachment:

Reference 5 Bad Bugs No Drugs No ESKAPE An Update from the Infectious Diseases Society of America

View Attachment:

Reference 50 Carbapenem Resistant Enterobacteriaceae Containing New Delhi Metallo Beta Lactamase in Two Patients Rhode Island March 2012

View Attachment:

Reference 51 First NDM Positive Salmonella sp Strain Identified in the United States

View Attachment:

Reference 52 Presence of Integron Associated Resistance in the Community Is Widespread and Contributes to Multidrug Resistance in the Hospital

View Attachment:

Reference 53 Carbapenem-Resistant Enterobacteriaceae--A Potential Threat

View Attachment:

Reference 54 Global Spread of Carbapenemase Producing Enterobacteriaceae

View Attachment:

Reference 55 Outcomes of Carbapenem--Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies

View Attachment:

Reference 56 Toxicity of Polymyxins A Systematic Review of the Evidence From Old and Recent Studies

View Attachment:

Reference 57 Vancomycin-Resistant Enterococci Mechanisms and Clinical Observations

View Attachment:

Reference 58 Major Trends in the Microbial Etiology of Nosocomial Infection

View Attachment:

Reference 59 Nosocomial Spread of Linezolid-Resistant, Vancomycin Resistant Enterococcus faecium

View Attachment:

Reference 6 Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens No ESKAPE

View Attachment:

Reference 60 Clinical Prevalence Antimicrobial Susceptibility and Geographic Resistant Patterns of Enterococci Results From the SENTRY Antimicrobial Surveillance Program 1997 1999

View Attachment:

Reference 61 Outcomes Associated With Vancomycin Resistant Enterococci: A Meta Analysis

View Attachment:

Reference 62 Comparison of Mortality Associated With Vancomycin Resistant and Vancomycin Susceptible Enterococcal Bloodstream Infections A MetaAnalysis

View Attachment:

Reference 63 Increase in Clostridium difficile Related Mortality Rates United States 1999 2004

View Attachment:

Reference 64 Global Tuberculosis Report 2012

View Attachment:

Reference 65 Fact Sheet Multi Drug Resistant Tuberculosis MDR TB

View Attachment:

Reference 66 Plan to Combat Extensively Drug Resistant Tuberculosis Recommendations of the Federal Tuberculosis Task Force

View Attachment:

Reference 67 Fact Sheet Trends in Tuberculosis 2011

View Attachment:

Reference 68 Mechanisms of Drug Resistance in Mycobacterium Tuberculosis

View Attachment:

Reference 69 Overview of Anti-Tuberculosis (TB) Drugs and Their Resistance Mechanisms

View Attachment:

Reference 7 Multidrug Resistant Acinetobacter Infection Mortality Rate and Length of Hospitalization

View Attachment:

Reference 70 Fact Sheet Extensively Drug Resistant Tuberculosis XDR TB

View Attachment:

Reference 71 Outbreak of Multidrug Resistant Tuberculosis at a Hospital New York City 1991

View Attachment:

Reference 72 Extensively Drug Resistant Tuberculosis in the United States 1993 2007

View Attachment:

Reference 73 2011 Sexually Transmitted Diseases Surveillance Gonorrhea

View Attachment:

Reference 74 Sexually Transmitted Diseases Treatment Guidelines 2010 Gonococcal Infections

View Attachment:

Reference 75 Sexually Transmitted Infections Among US Women and Men Prevalence and Incidence Estimates 2008

View Attachment:

Reference 76 Antimicrobial Resistance in Neisseria gonorrhoeae in the United States 1988 1994 The Emergence of Decreased Susceptibility to the Fluoroquinolones

View Attachment:

Reference 77 Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections

View Attachment:

Reference 78 The Emerging Threat of Untreatable Gonococcal Infection

View Attachment:

Reference 79 Meningococcal Disease

View Attachment:

Reference 8 The Emergence and Implications of Metallo-Beta Lactamases in Gram Negative Bacteria

View Attachment:

Reference 80 Meningococcal Meningitis

View Attachment:

Reference 81 Active Bacterial Core Surveillance ABCs Report Neisseria meningitidis 2010

View Attachment:

Reference 82 Manual for the Surveillance of Vaccine Preventable Diseases

View Attachment:

Reference 83 Antimicrobial Drug Resistance Clinical and Epidemiological Aspects Vol 2

View Attachment:

Reference 84 Emergence of Ciprofloxacin Resistant Neisseria meningitidis in North America

View Attachment:

Reference 85 Antibiotic Resistance in Neisseria meningitidis

View Attachment:

Reference 86 Antimicrobial Susceptibility Testing, Drug Resistance Mechanisms, and Therapy of Infections With Nontuberculous Mycobacteria

View Attachment:

Reference 87 An Official ATS IDSA Statement Diagnosis Treatment and Prevention of Nontuberculous Mycobacterial Diseases

View Attachment:

Reference 88 Nontuberculous Mycobacteria Associated Lung Disease in Hospitalized Persons United States 1998 2005

View Attachment:

Reference 89 Prevalence of Nontuberculous Mycobacterial Lung Disease in US Medicare Beneficiaries

View Attachment:

Reference 9 Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa

View Attachment:

Reference 90 Isolation Prevalence of Pulmonary Non Tuberculous Mycobacteria in Ontario 1997 2003

View Attachment:

Reference 91 Resistance Mechanisms and Drug Susceptibility Testing of Nontuberculous Mycobacteria

View Attachment:

Reference 92 Nontuberculous Mycobacterial Disease

View Attachment:

Reference 93 Cefepime-Resistant Pseudomonas aeruginosa

View Attachment:

Reference 94 The Epidemiological Profile of Infections With Multidrug Resistant Pseudomonas aeruginosa and Acinetobacter Species

View Attachment:

Reference 95 Bacteraemia Due to Pseudomonas putida and Other Pseudomonas Non aeruginosa in Children

View Attachment:

Reference 96 Vancomycin-Intermediate Resistant Staphylococcus VISA VRSA in Healthcare Settings

View Attachment:

Reference 97 Predictors of Clinical Virulence in Community Onset Methicillin Resistant Staphylococcus aureus Infections The Importance of USA300 and Pneumonia

View Attachment:

Reference 98 Emergence of Community Acquired Methicillin Resistant Staphylococcus aureus USA 300 Clone as the Predominant Cause of Skin and Soft Tissue Infections

View Attachment:

Reference 99 Invasive Methicillin Resistant Staphylococcus aureus Infections in the United States

View Attachment:

Document ID: FDA-2012-N-1037-0013
Document Type: Proposed Rule
Agency: Food And Drug Administration
Topics: Drugs, Health, Health Care, Immunization, Prescription Drugs, Public Health
Federal Register Number: 2013-13865
CFR Citation: 21 CFR Part 317
View Document:

Establishing a List of Qualifying Pathogens Under the Food and Drug Administration Safety and Innovation Act

Details Information

Attachments:

List of References 1 through 157

Refeence 148 Increase in Pneumococcus Macrolide Resistance United States

Reference 1 Hospital and Societal Costs of Antimicrobial Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship

Reference 10 Clinical Outcomes of Health Care Associated Infections and Antimicrobial Resistance in Patients Admitted to European Intensive Care Units: A Cohort Study

Reference 100 Mechanisms of Antibiotic Resistance in Staphylococcus aureus

Reference 101 Staphylococcus aureus Resistant to Vancomycin United States 2002

Reference 102 Clinical Practice Guideline by the Infectious Disease Society of America for the Treatment of Methicillin Resistant Staphylococcus Aureus Infections in Adults and Children

Reference 103 Resistance of Group B Streptococcus to Selected Antibiotics Including Erythromycin and Clindamycin

Reference 104 Group B Strep GBS Fast Facts

Reference 105 Group B Strep Infection in Newborns

Reference 106 Group B Strep Infection in Adults

Reference 107 Antibiotic Resistance Patterns in Invasive Group B Streptococcal Isolates

Reference 108 Mutation in the Group B Streptococcal pbp2x Gene Conferring Decreased Susceptibility to Beta Lactam Antibiotics

Reference 109 Resistance to Beta Lactam Antibiotics

Reference 11 Aspergillus Infection in Lung Transplant Patients Incidence and Prognosis

Reference 110 Genetic Heterogeniety in pbp Genes Among Clinically Isolated Group B Streptococci With Reduced Penicillin Susceptibility

Reference 111 In Vitro Resistance to Macrolides and Clindamycin by Group B Streptococcus Isolated From Pregnant and Nonpregnant Women

Reference 112 Infectious Diseases Related to Travel Pneumococcal Disease Streptococcus pneumoniae

Reference 113 Streptococcus pneumoniae: Does Antimicrobial Resistance Matter

Reference 114 Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23 Valent Pneumococcal Polysaccharide Vaccine PPSV23

Reference 115 Disease Listing Streptococcus pneumoniae Disease

Reference 116 Drug Resistant Streptococcus pneumoniae Rational Antibiotic Choices

Reference 117 Changing Trends in Antimicrobial Resistance and Serotypes of Streptococcus pneumoniae Isolates in Asian Countries an Asian Network for Surveillance of Resistant Pathogens ANSORP Study

Reference 118 Antimicrobial Resistance Surveillance in Europe 2009

Reference 119 The Streptococcus pyogenes Proteome Maps Virulence Factors and Vaccine Candidates

Reference 12 Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism

Reference 120 Diagnosis and Management of Adults With Pharyngitis A Cost Effectiveness Analysis

Reference 121 Group A Streptococcal Pharyngitis and Immune Mediated Complications From Diagnosis to Management

Reference 122 ABCs Report Group A Streptococcus 2011

Reference 123 Why Have Group A Streptococci Remained Susceptible to Penicillin Report on a Symposium

Reference 124 Group A Streptococcus and its Antibiotic Resistance

Reference 125 Cholera Epidemiology and Risk Factors

Reference 126 Cholera in the United States 1995 2000: Trends at the End of the Twentieth Century

Reference 127 Drug Resistance Mechanisms in Vibrio cholerae O1 Outbreak Strain Haiti 2010

Reference 128 Third Generation Cephalosporin Resistant Vibrio cholerae India

Reference 129 Toxigenic Vibrio cholerae Serogroup O141 Associated Cholera Like Diarrhea and Bloodstream Infection in the United States

Reference 13 Azole Antifungal Resistance Today Focus on Aspergillus

Reference 130 The Current ICE Age Biology and Evolution of SXT Related Integrating Conjugative Elements

Reference 131 Cholera Treatment

Reference 132 Antimicrobial Resistant Pathogens Associated With Healthcare Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention 2009 2010

Reference 133 Pan Resistant Acinetobacter Infection in Neonates in Karachi Pakistan

Reference 134 National Antimicrobial Resistance Monitoring System Enteric Bacteria: 2010 Human Isolates Final Report

Reference 135 The Roles of Clostridium difficile and Norovirus Among Gastroenteritis Associated Deaths in the United States 1999 2007

Reference 136 Making Health Care Safer: Stop Infections from Lethal CRE Germs Now

Reference 137 Mycobacterium General Characteristics Laboratory Detection and Staining Procedures

Reference 138 Rifampin Resistant Meningococcal Disease

Reference 139 Epidemiology of Invasive Meningococcal Disease With Decreased Susceptibility to Penicillin in Ontario Canada 2000 to 2006

Reference 14 An outbreak of Burkholderia cepacia Bacteremia in Hospitalized Hematology Patients Selectively Affecting Those With Acute Myeloid Leukemia

Reference 140 Antibiotic Treatment Recommendations for the Use of Antibiotics for the Treatment of Cholera

Reference 141 Laboratory Based Surveillance of Neisseria meningitides Isolates From Disease Cases in Latin America and Caribbean Countries SIREVA II 2006 2010

Reference 142 Fluoroquinolone Resistance in Neisseria meningitidis in Spain

Reference 143 Emergence of Neisseria meningitidis With Decreased Susceptibility to Ciprofloxacin in Argentina

Reference 144 Mutator Clones of Neisseria meningitidis in Epidemic Serogroup A Disease

Reference 145 Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus aureus United States 1999 2005

Reference 146 ABCs Report Methicillin Resistant Staphylococcus aureus 2010

Reference 147 Emergence of a Multiresistant Serotype 19A Pneumococcal Strain Not Included in the 7 Valent Conjugate Vaccine as an Otopathogen in Children

Reference 149 Clinical Data in Children With Meningococcal Meningitis in a Spanish Hospital

Reference 15 Clinical Characteristics and Outcomes of Patients With Burkholderia cepacia Bacteremia in an Intensive Care Unit

Reference 150 Burkholderia cenocepacia and Burkholderia multivorans Influence on Survival in Cystic Fibrosis

Reference 151 Overview of Nosocomial Infections Caused by Gram Negative Bacilli

Reference 152 Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa Our Worst Nightmare

Reference 153 CDC Grand Rounds The Growing Threat of Multidrug Resistant Gonorrhea

Reference 154 Antimicrobial Resistance Trends of Shigella Serotypes in New York City 2006 2009

Reference 155 Antimicrobial Resistance in Nontyphoidal Salmonella

Reference 156 The Relation Between Farm Specific Factors and Prevalence of Clostridium difficile in Slaughter Pigs

Reference 157 Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America

Reference 16 An Episodic Outbreak of Genetically Related Burkholderia cepacia Among Non-Cystic Fibrosis Patients at a University Hospital

Reference 17 Predictors of Mortality in Adults With Cystic Fibrosis

Reference 18 Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health

Reference 19 Antibiotic Resistance in Burkholderia cepacia at Two Regional Centres in Northern Ireland: Is There a Need for Synergy Testing

Reference 2 The Global Impact of Drug Resistance

Reference 20 Cystic Fibrosis Foundation Achieving the Mission

Reference 21 Campylobacter General Information

Reference 22 Antibiotic Resistance in Campylobacter Emergence Transmission and Persistence

Reference 23 Antimicrobial Resistance Virulence and Genotypic Profile Comparison of Campylobacter jejuni and Campylobacter coli Isolated from Humans and Retail Meats

Reference 24 Trends in Antibiotic Sensitivity Pattern and Molecular Detection of tet O Mediated Tetracycline Resistance in Campylobacter jejuni Isolates From Human and Poultry Sources

Reference 25 Treatment of Invasive Candidiasis in Neutropenic Patients Systematic Review of Randomized Controlled Treatment Trials